High Plasma Sphingosine 1-phosphate Levels Predict Osteoporotic Fractures in Postmenopausal Women: The Center of Excellence for Osteoporosis Research Study
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: Higher sphingosine 1-phosphate (S1P) plasma levels are associated with decreased bone mineral density (BMD), and increased risk of prevalent vertebral fracture. So, we hypothesized that postmenopausal women with increased baseline plasma S1P levels have a greater risk for future incident fracture (osteoporosis-related fractures [ORFs]). Methods: This study was conducted in a prospective longitudinal cohort of 707 women recruited in 2004 and followed up annually for a mean period of 5.2±1.3 years. They were postmenopausal (aged ≥50 years). The primary outcome measure was the time to the first confirmed ORF event using radiographs and/or a surgical report. Results: The plasma S1P levels (μmol/L) were significantly higher in the women with incident fracture (7.23±0.79) than in those without ORFs (5.02±0.51; P<0.001). High S1P levels were strongly associated with increased fracture risk. After adjustment for age and other confounders, the hazard ratio (HR) was 6.12 (95% confidence interval [CI], 4.92-7.66) for each 1-standard deviation increase in plasma S1P levels. The women in the highest quartile of S1P levels had a significant increase in fracture risk (HR, 9.89; 95% CI, 2.83-34.44). Results were similar when we compared plasma S1P levels at the 1-year visit. Conclusions: The associations between plasma S1P levels and fracture risk were independent of BMD and other confounders. These findings demonstrate that high plasma S1P level at baseline and at years 1 to 5 is a strong and independent risk factor for future [ORFs] among postmenopausal women and could be a useful biomarker for fracture risk assessment in this population.
Abstract
Background: Higher sphingosine 1-phosphate (S1P) plasma levels are associated with decreased bone mineral density (BMD), and increased risk of prevalent vertebral fracture. So, we hypothesized that postmenopausal women with increased baseline plasma S1P levels have a greater risk for future incident fracture (osteoporosis-related fractures [ORFs]). Methods: This study was conducted in a prospective longitudinal cohort of 707 women recruited in 2004 and followed up annually for a mean period of 5.2±1.3 years. They were postmenopausal (aged ≥50 years). The primary outcome measure was the time to the first confirmed ORF event using radiographs and/or a surgical report. Results: The plasma S1P levels (μmol/L) were significantly higher in the women with incident fracture (7.23±0.79) than in those without ORFs (5.02±0.51; P<0.001). High S1P levels were strongly associated with increased fracture risk. After adjustment for age and other confounders, the hazard ratio (HR) was 6.12 (95% confidence interval [CI], 4.92-7.66) for each 1-standard deviation increase in plasma S1P levels. The women in the highest quartile of S1P levels had a significant increase in fracture risk (HR, 9.89; 95% CI, 2.83-34.44). Results were similar when we compared plasma S1P levels at the 1-year visit. Conclusions: The associations between plasma S1P levels and fracture risk were independent of BMD and other confounders. These findings demonstrate that high plasma S1P level at baseline and at years 1 to 5 is a strong and independent risk factor for future [ORFs] among postmenopausal women and could be a useful biomarker for fracture risk assessment in this population.
참고문헌 (33)
- Garnero P, "Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women", J Musculoskelet Neuronal Interact, 4, pp.50~63 (2004)
- Sattui SE, "Fracture mortality: associations with epidemiology and osteoporosis treatment", Nat Rev Endocrinol, 10, pp.592~602 (2014)[DOI]
- Chopin F, "Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis", Joint Bone Spine, 79, pp.26~31 (2012)[DOI]
- Garnero P, "Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study", J Bone Miner Res, 17, pp.826~833 (2002)[DOI]
- Ardawi MS, "High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study", J Bone Miner Res, 27, pp.2592~2602 (2012)[DOI]
- Proia RL, "Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy", J Clin Invest, 125, pp.1379~1387 (2015)[DOI]
- Rosen H, "Sphingosine-1-phosphate and its receptors: structure, signaling, and influence", Annu Rev Biochem, 82, pp.637~662 (2013)[DOI]
- Ishii M, "Sphingosine-1-phosphate signaling controlling osteoclasts and bone homeostasis", Biochim Biophys Acta, 1831, pp.223~227 (2013)[DOI]
- Ryu J, "Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling", EMBO J, 25, pp.5840~5851 (2006)[DOI]
- Ishii M, "Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo", J Exp Med, 207, pp.2793~2798 (2010)[DOI]
- Ishii M, "Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis", Nature, 458, pp.524~528 (2009)[DOI]
- Kim BJ, "Plasma sphingosine 1-phosphate levels and the risk of vertebral fracture in postmenopausal women", J Clin Endocrinol Metab, 97, pp.3807~3814 (2012)[DOI]
- Heilmann A, "Systemic treatment with the sphingosine-1-phosphate analog FTY720 does not improve fracture healing in mice", J Orthop Res, 31, pp.1845~1850 (2013)
- Grey A, "The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinase", Endocrinology, 143, pp.4755~4763 (2002)[DOI]
- Lotinun S, "Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation", J Clin Invest, 123, pp.666~681 (2013)
- Sefcik LS, "Selective activation of sphingosine 1-phosphate receptors 1 and 3 promotes local microvascular network growth", Tissue Eng Part A, 17, pp.617~629 (2011)[DOI]
- Rouzi AA, "Independent predictors of all osteoporosis-related fractures among healthy Saudi postmenopausal women: the CEOR Study", Bone, 50, pp.713~722 (2012)[DOI]
- World Health Organization, "International statistical classification of diseases and related health problems 10th revision (ICD-10)" (1992), World Health Organization
- Genant HK, "Vertebral fracture assessment using a semiquantitative technique", J Bone Miner Res, 8, pp.1137~1148 (1993)
- Lai WQ, "Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis", J Immunol, 181, pp.8010~8017 (2008)[DOI]
- Ardawi MS, "Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study", Bone, 47, pp.804~814 (2010)[DOI]
- Ardawi MS, "Determinants of serum sclerostin in healthy pre- and postmenopausal women", J Bone Miner Res, 26, pp.2812~2822 (2011)[DOI]
- Hennekens CH, "Epidemiology in medicine", pp.87~95 (1997), Little, Brown and Company
- Lee SH, "Higher circulating sphingosine 1-phosphate levels are associated with lower bone mineral density and higher bone resorption marker in humans", J Clin Endocrinol Metab, 97, pp.E1421~E1428 (2012)[DOI]
- Ivaska KK, "Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years", J Bone Miner Res, 25, pp.393~403 (2010)[DOI]
- Grey A, "Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphate", Calcif Tissue Int, 74, pp.542~550 (2004)[DOI]
- Roelofsen T, "Sphingosine-1-phosphate acts as a developmental stage specific inhibitor of platelet-derived growth factor-induced chemotaxis of osteoblasts", J Cell Biochem, 105, pp.1128~1138 (2008)[DOI]
- Peest U, "S1P-lyase independent clearance of extracellular sphingosine 1-phosphate after dephosphorylation and cellular uptake", J Cell Biochem, 104, pp.756~772 (2008)[DOI]
- Maeda Y, "Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow", Int Immunol, 22, pp.515~525 (2010)[DOI]
- Armas LA, "Pathophysiology of osteoporosis: new mechanistic insights", Endocrinol Metab Clin North Am, 41, pp.475~486 (2012)[DOI]
- Rivera J, "The alliance of sphingosine-1-phosphate and its receptors in immunity", Nat Rev Immunol, 8, pp.753~763 (2008)[DOI]
- Kim BJ, "The effect of sphingosine-1-phosphate on bone metabolism in humans depends on its plasma", bone marrow gradient, 2016, pp.39, 297~303
- Bae SJ, "The circulating sphingosine-1-phosphate level predicts incident fracture in postmenopausal women: a 3.5-year follow-up observation study", Osteoporos Int, 27, pp.2533~2541 (2016)[DOI]